AI Article Synopsis

  • The nuclear lamina components, previously thought to just provide structure to the nucleus, are now linked to various diseases like cancer due to their mutations and misregulation.
  • Research shows that higher levels of Lamin A/C are associated with lower survival rates in glioblastoma multiforme (GBM) patients from The Cancer Genome Atlas.
  • In experiments, increased Lamin A/C expression was found to enhance tumor aggressiveness, and the mTORC2 component Rictor is identified as a key player in this process.

Article Abstract

Nuclear lamina components have long been regarded as scaffolding proteins, forming a dense fibrillar structure necessary for the maintenance of the nucleus shape in all the animal kingdom. More recently, mutations, aberrant localisation and deregulation of these proteins have been linked to several diseases, including cancer. Using publicly available data we found that the increased expression levels of the nuclear protein Lamin A/C correlate with a reduced overall survival in The Cancer Genome Atlas Research Network (TCGA) patients affected by glioblastoma multiforme (GBM). We show that the expression of the gene is linked to the enrichment of cancer-related pathways, particularly pathways related to cell adhesion and cell migration. Mimicking the modulation of in a GBM preclinical cancer model, we confirmed both in vitro and in vivo that the increased expression of is associated with an increased aggressiveness and tumorigenicity. In addition, delving into the possible mechanism behind -induced GBM aggressiveness and tumorigenicity, we found that the mTORC2 component, Rictor, plays a central role in mediating these effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533312PMC
http://dx.doi.org/10.3390/biomedicines9101343DOI Listing

Publication Analysis

Top Keywords

aggressiveness tumorigenicity
12
lamin a/c
8
glioblastoma multiforme
8
increased expression
8
role lamin
4
a/c candidate
4
candidate biomarker
4
biomarker aggressiveness
4
tumorigenicity glioblastoma
4
multiforme nuclear
4

Similar Publications

Background: Hepatocellular carcinoma (HCC) is a prevalent and aggressive tumor. Sorafenib is the first-line treatment for patients with advanced HCC, but resistance to sorafenib has become a significant challenge in this therapy. Cancer stem cells play a crucial role in sorafenib resistance in HCC.

View Article and Find Full Text PDF

Mitochondrial transcription elongation factor TEFM promotes malignant progression of gliomas.

Cancer Cell Int

December 2024

Institute for Excellence in Clinical Medicine of Kunshan First People's Hospital, Soochow University, Suzhou, China.

Gliomas are the most common tumors of the central nervous system, with glioblastoma (GBM) being particularly aggressive and fatal. Current treatments for GBM, including surgery and chemotherapy, are limited by tumor aggressiveness and the blood-brain barrier. Therefore, understanding the molecular mechanisms driving GBM growth is essential.

View Article and Find Full Text PDF

Ductal carcinoma in situ (DCIS) is a noninvasive breast disease that variably progresses to invasive breast cancer (IBC). Given the unpredictability of this progression, most DCIS patients are aggressively managed similar to IBC patients. Undoubtedly, this treatment paradigm places many DCIS patients at risk of overtreatment and its significant consequences.

View Article and Find Full Text PDF

E2F1-driven CENPM expression promotes glycolytic reprogramming and tumorigenicity in glioblastoma.

Cell Biol Toxicol

December 2024

Department of Neurosurgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.

Centromere protein M (CENPM), traditionally associated with chromosome segregation, is now recognized for its significant role in cancer biology. Particularly in glioblastoma (GBM), where less is known about CENPM compared to other centromere proteins (CENPs), it appears crucially involved in regulating tumor cell proliferation, invasion, and metabolic reprogramming-key factors in GBM's aggressiveness. Initial analyses using the GEPIA database (TCGA/GTEx datasets) reveal distinct patterns of CENPM expression in GBM, suggesting its potential as a therapeutic target.

View Article and Find Full Text PDF

Liquidambaric acid inhibits cholangiocarcinoma progression by disrupting the STAMBPL1/NRF2 positive feedback loop.

Phytomedicine

December 2024

The Department of Hepato-biliary-pancreatic Surgery, The Institute of Hepatobiliary and Pancreatic Diseases, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, PR China; Changzhou Medical Center, Nanjing Medical University, Changzhou, PR China. Electronic address:

Background: Abnormal antioxidant capacity in cancer cells is intimately linked to tumor aggressiveness. Modulating oxidative stress status and inhibiting ferroptosis represents a novel anticancer therapeutic strategy. STAM Binding Protein Like 1 (STAMBPL1), a deubiquitinase, is implicated in various malignancies, yet its function in inhibiting ferroptosis and therapeutic potential for cholangiocarcinoma (CCA) remains unexplored.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!